SER-109, an Investigational Microbiome Drug to Reduce Recurrence After <i>Clostridioides difficile</i> Infection: Lessons Learned From a Phase 2 Trial
2020152 citationsJournal Articlehybrid Open Access
Field-Weighted Citation Impact: 2.48
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After <i>Clostridioides difficile</i> Infection: Lessons Learned From a Phase 2 Trial | Researchclopedia